RASSF1 Primary Antibody
|Aliases||123F2; RDA32; NORE2A; RASSF1A; REH3P21|
|Formulation||Ascitic fluid containing 0.03% sodium azide.|
|Immunogen||Purified recombinant fragment of human RASSF1 expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|IHC_P(Immunohistochemistry)||1/200 - 1/1000|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Figure 1: Western blot analysis using RASSF1 mouse mAb against HepG2 (1) and Jurkat (2) cell lysate.
Figure 2: Flow cytometric analysis of HepG2 cells using RASSF1 mouse mAb (green) and negative control (purple).
Figure 3: Immunohistochemical analysis of paraffin-embedded rectum cancer tissues using RASSF1 mouse mAb with DAB staining.
Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);
|Description||This gene encodes a protein similar to the RAS effector proteins. Loss or altered expression of this gene has been associated with the pathogenesis of a variety of cancers, which suggests the tumor suppressor function of this gene. The inactivation of this gene was found to be correlated with the hypermethylation of its CpG-island promoter region. The encoded protein was found to interact with DNA repair protein XPA. The protein was also shown to inhibit the accumulation of cyclin D1, and thus induce cell cycle arrest. Several alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. |
|References (references)||1.Cancer Res. 2012 May 1;72(9):2206-17. |
2.Cancer Biomark. 2011-2012;10(1):13-26.